文献速递临床免疫质量管理与危急值

抗可提取核抗原(ENA)检测方法与质量保证实践:EFLM国际调查

Methodology and quality assurance practices in performing anti-extractable nuclear antigen (ENA) analysis: an EFLM report on an international survey.
PubMed 文献 · Clin Chem Lab Med · 2026-06-08

该国际调查由EFLM开展,收集427家实验室抗ENA检测方法与质量保证实践数据。结果显示方法、周转时间、批间变异评估和验证策略差异显著;虽多数实验室开展室内质控和室间质评,但试剂批号评估和验证策略仍不统一,需更全面推荐。

要点

  • 52%实验室使用两种或以上抗ENA方法,71%在72小时内完成检测。
  • 91%开展室内质控,87%参加室间质评,但仅36%评估试剂批号。
  • 81%进行方法验证,但样本类型、数量和重复性方案差异大。

核心结论

  • 抗ENA实验室实践存在显著异质性,方法、周转时间、批间变异评估和验证策略差异大。

研究设计与样本

  • EFLM国际调查,通过Sciensano、国家EASI组和ICAP分发问卷,共427家实验室参与。

主要发现

  • 52%实验室使用两种或以上抗ENA方法,71%在72小时内完成分析,42%提供紧急检测。
  • 91%实验室开展室内质控,主要使用商业质控品;87%参加室间质评,近半每年参加超过三次。

临床怎么用

  • 检验科应关注抗ENA方法选择、周转时间、试剂批号评估和方法验证的规范化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Autoantibodies to extractable nuclear antigens (anti-ENA) play a crucial role in the diagnosis of systemic autoimmune rheumatic diseases (SARD). Analytical methods differ in antigen composition and diagnostic performance. We aimed to document the extent of variability amongst laboratories in how anti-ENA testing is conducted, controlled and verified. METHODS: A survey was developed to collect information on anti-ENA methodology and quality assurance practices. The questionnaire was distributed amongst laboratories by Sciensano (Belgium), national EASI groups (Italy, Croatia, Portugal, Estonia, Greece) and ICAP (worldwide). RESULTS: A total of 427 laboratories participated (61 % European, 21 % American, 14 % Asian). More than half (52 %) use two or more anti-ENA methods. Turnaround time varied, but 71 % perform the analysis within 72 h. Urgent testing was offered in 42 % of laboratories. Internal quality control (IQC) was performed in 91 % of laboratories, predominantly with commercial materials. External quality assessment (EQA) participation was also high (87 %), with nearly half participating in more than three distributions annually. Reagent lot evaluation was less widely implemented (36 %). Forty-three percent tried to limit variability by limiting lot changes. Method verification was performed by 81 % of the laboratories, though sample type and numbers, as well as reproducibility replicates varied considerably. CONCLUSIONS: This survey highlights substantial heterogeneity in anti-ENA laboratory practice. While most laboratories apply IQC and EQA, significant variation remains in test method(s), turnaround times, lot variability evaluation and verification strategies. Development of more comprehensive recommendations on these topics are essential to improve reliability and comparability of results across laboratories.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Gijbels E, De Koninck S, Broeders S, et al. Methodology and quality assurance practices in performing anti-extractable nuclear antigen (ENA) analysis: an EFLM report on an international survey. Clin Chem Lab Med. 2026. PMID: 42251762. doi:10.1515/cclm-2026-0273

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。